Gout is a type of arthritis that occurs due to the buildup of uric acid crystals in the joints, causing inflammation, swelling, and intense pain.

What is the gout therapeutics market?

The gout therapeutics market comprises medications and treatments used to manage and alleviate the symptoms of gout, including reducing inflammation, relieving pain, and lowering uric acid levels in the body.

What are the common medications used in gout therapeutics?

Common medications used in gout therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and urate-lowering agents such as xanthine oxidase inhibitors and uricosuric agents.

How is the gout therapeutics market growing?

The gout therapeutics market has been growing steadily due to the increasing prevalence of gout worldwide, rising awareness and diagnosis rates, and the development of novel and more effective therapies for gout management.

What are the key factors driving the gout therapeutics market?

Key factors driving the gout therapeutics market include the growing aging population, unhealthy dietary habits, sedentary lifestyles, obesity, and the rising incidence of comorbidities such as hypertension and diabetes, which are associated with gout.

Global Gout Therapeutics Market By Drug Class (NSAIDs, Corticosteroids, Colchicine, and Urate-Lowering Agents), By Disease Condition (Acute Gout, and Chronic Gout), By End-User (Hospitals, Clinics, and Home Care Setting), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Published date: Oct 2023
Report ID: 64332
Number of Pages: 393
Format:

- Pfizer Inc Company Profile
- AbbVie Inc. Company Profile
- Novartis AG Company Profile
- Amgen Inc
- Merck & Co Inc
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals Industries Ltd
- AstraZeneca Plc Company Profile
- Boehringer Ingelheim International GmbH
- GSK plc
- Antares Pharma
- Astellas Pharma Inc
- JW Pharmaceutical Corporation
- Addex Therapeutics
- Takeda Pharmaceutical Company Limited
- TEIJIN LIMITED
- Lilly

Related Reports

Our Clients

Report ID 64332
Published Date Oct 2023
Rating
- ★★★★★
  
  ★★★★★
- (39)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible